HRP20251413T1 - Nove soli trimetazidina - Google Patents
Nove soli trimetazidinaInfo
- Publication number
- HRP20251413T1 HRP20251413T1 HRP20251413TT HRP20251413T HRP20251413T1 HR P20251413 T1 HRP20251413 T1 HR P20251413T1 HR P20251413T T HRP20251413T T HR P20251413TT HR P20251413 T HRP20251413 T HR P20251413T HR P20251413 T1 HRP20251413 T1 HR P20251413T1
- Authority
- HR
- Croatia
- Prior art keywords
- trimetazidine
- acid
- pharmaceutical composition
- composition according
- salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21306465 | 2021-10-20 | ||
| EP22808665.8A EP4419510B1 (en) | 2021-10-20 | 2022-10-19 | Novel trimetazidine salts |
| PCT/EP2022/079054 WO2023066971A1 (en) | 2021-10-20 | 2022-10-19 | Novel trimetazidine salts |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20251413T1 true HRP20251413T1 (hr) | 2025-12-19 |
Family
ID=78592764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20251413TT HRP20251413T1 (hr) | 2021-10-20 | 2022-10-19 | Nove soli trimetazidina |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20250250245A1 (enExample) |
| EP (1) | EP4419510B1 (enExample) |
| JP (1) | JP2024539090A (enExample) |
| KR (1) | KR20240093576A (enExample) |
| CN (1) | CN118076591A (enExample) |
| AR (1) | AR127403A1 (enExample) |
| AU (1) | AU2022369026A1 (enExample) |
| CR (1) | CR20240157A (enExample) |
| DK (1) | DK4419510T3 (enExample) |
| ES (1) | ES3057370T3 (enExample) |
| HR (1) | HRP20251413T1 (enExample) |
| IL (1) | IL311916A (enExample) |
| LT (1) | LT4419510T (enExample) |
| MA (1) | MA66951B1 (enExample) |
| MX (1) | MX2024004714A (enExample) |
| PL (1) | PL4419510T3 (enExample) |
| PT (1) | PT4419510T (enExample) |
| RS (1) | RS67449B1 (enExample) |
| SI (1) | SI4419510T1 (enExample) |
| WO (1) | WO2023066971A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025106477A1 (en) * | 2023-11-14 | 2025-05-22 | Samsara Therapeutics Inc. | Novel autophagy inducing compounds and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104138376A (zh) * | 2013-05-06 | 2014-11-12 | 常州高新技术产业开发区三维工业技术研究所有限公司 | 一种提高缺氧耐受力的缓释剂 |
| FR3027803B1 (fr) | 2014-11-05 | 2018-02-09 | Les Laboratoires Servier | Composition pharmaceutique comprenant un betabloquant et un inhibiteur de l'enzyme de conversion |
| CN105287564A (zh) * | 2015-09-06 | 2016-02-03 | 余祖江 | 一种防治肝病的西药复合物及其用途 |
| CN110183398B (zh) | 2019-05-14 | 2021-06-29 | 中南民族大学 | 一种曲美他嗪草酸盐及其制备方法和应用 |
| CN110105307B (zh) | 2019-05-14 | 2021-06-01 | 中南民族大学 | 一种曲美他嗪草酸盐及其制备方法和应用 |
| CN110054599B (zh) * | 2019-05-14 | 2021-05-07 | 中南民族大学 | 一种曲美他嗪草酸盐及其制备方法和应用 |
| CN112043691A (zh) * | 2019-06-06 | 2020-12-08 | 常州高新技术产业开发区三维工业技术研究所有限公司 | 一种药物组合物及其用途 |
-
2022
- 2022-10-19 RS RS20251183A patent/RS67449B1/sr unknown
- 2022-10-19 MX MX2024004714A patent/MX2024004714A/es unknown
- 2022-10-19 CR CR20240157A patent/CR20240157A/es unknown
- 2022-10-19 LT LTEPPCT/EP2022/079054T patent/LT4419510T/lt unknown
- 2022-10-19 US US18/702,363 patent/US20250250245A1/en active Pending
- 2022-10-19 AR ARP220102840A patent/AR127403A1/es unknown
- 2022-10-19 EP EP22808665.8A patent/EP4419510B1/en active Active
- 2022-10-19 IL IL311916A patent/IL311916A/en unknown
- 2022-10-19 PL PL22808665.8T patent/PL4419510T3/pl unknown
- 2022-10-19 AU AU2022369026A patent/AU2022369026A1/en active Pending
- 2022-10-19 ES ES22808665T patent/ES3057370T3/es active Active
- 2022-10-19 SI SI202230206T patent/SI4419510T1/sl unknown
- 2022-10-19 PT PT228086658T patent/PT4419510T/pt unknown
- 2022-10-19 DK DK22808665.8T patent/DK4419510T3/da active
- 2022-10-19 HR HRP20251413TT patent/HRP20251413T1/hr unknown
- 2022-10-19 WO PCT/EP2022/079054 patent/WO2023066971A1/en not_active Ceased
- 2022-10-19 MA MA66951A patent/MA66951B1/fr unknown
- 2022-10-19 JP JP2024523404A patent/JP2024539090A/ja active Pending
- 2022-10-19 CN CN202280068113.8A patent/CN118076591A/zh active Pending
- 2022-10-19 KR KR1020247015968A patent/KR20240093576A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL311916A (en) | 2024-06-01 |
| CR20240157A (es) | 2024-05-22 |
| EP4419510B1 (en) | 2025-10-08 |
| ES3057370T3 (en) | 2026-03-02 |
| WO2023066971A1 (en) | 2023-04-27 |
| JP2024539090A (ja) | 2024-10-28 |
| LT4419510T (lt) | 2025-12-29 |
| CN118076591A (zh) | 2024-05-24 |
| CA3234743A1 (en) | 2023-04-27 |
| US20250250245A1 (en) | 2025-08-07 |
| RS67449B1 (sr) | 2025-12-31 |
| AR127403A1 (es) | 2024-01-17 |
| KR20240093576A (ko) | 2024-06-24 |
| EP4419510A1 (en) | 2024-08-28 |
| MA66951B1 (fr) | 2025-12-31 |
| AU2022369026A1 (en) | 2024-05-02 |
| PT4419510T (pt) | 2026-01-02 |
| SI4419510T1 (sl) | 2026-01-30 |
| MX2024004714A (es) | 2024-05-10 |
| DK4419510T3 (da) | 2025-11-17 |
| PL4419510T3 (pl) | 2026-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2013318182C1 (en) | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 | |
| JP2016512822A5 (enExample) | ||
| US6734203B2 (en) | Fused imidazolium derivatives | |
| IL298769A (en) | Benzofuran compounds are useful for mental disorders or mental enhancement | |
| Simons et al. | A new class of chiral modifiers for the enantioselective hydrogenation of α-ketoesters with PtAl2O3 | |
| US3253037A (en) | N-2-alkynyl-amino-benzocylo-alkanes | |
| US9676708B2 (en) | Controlled HNO release through intramolecular cyclization-elimination | |
| CN115190815A (zh) | 芳基环己基胺衍生物及其在精神障碍的治疗中的用途 | |
| HUP0104218A2 (hu) | Új szubsztituált fenil-ciklohexil vegyületekből származó észterek | |
| CA2851433A1 (en) | R(+)-n-methyl-propargyl-aminoindan | |
| CN106458866A (zh) | 氨基羰基氨基甲酸酯化合物 | |
| WO2001072709A1 (en) | Naphtalene derivatives and their pharmaceutical use | |
| TW200918506A (en) | Indane-amine derivatives, their preparation and use as medicaments | |
| BR102012024778A2 (pt) | Compostos heteroaromáticos; processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica | |
| US3061517A (en) | Antihistamine composition and method | |
| JP2024539090A5 (enExample) | ||
| JP2010520173A (ja) | 新規剤形 | |
| US20110189280A1 (en) | Dosage form comprising 1-isopropyl-4-hexahydro-1h-1,4-diazepine or a salt thereof | |
| US3830827A (en) | L-alpha-hydrazino-alpha-substituted-beta-(3,4-dihydroxyphenyl)propionic acid substantially free of the d isomer,the lower alkyl esters thereof,and the pharmaceutically acceptable salts thereof,wherein the substituent is lower alkyl | |
| CN105175307A (zh) | Lu AE58054的盐酸盐晶型A及其制备方法和用途 | |
| PL129370B1 (en) | Process for preparing novel derivatives of halophenylpyridylallylamine | |
| JPS6124388B2 (enExample) | ||
| KR20200071107A (ko) | (r)-9-(2,5-디플루오로페네틸)-4-에틸-2-메틸-1-옥사-4,9-디아자스피로[5.5]운데칸-3-온의 염 | |
| PL100989B1 (pl) | Sposob otrzymywania pochodnych kwasu l-alfa-hydrazyno-beta-fenylopropionowego | |
| CN118076591A (zh) | 新的曲美他嗪盐 |